Encouraging the Alabama Medicaid Agency to evaluate the overall costs of GLP-1 medications and report its findings

HR 166 is a resolution encouraging the Alabama Medicaid Agency to evaluate the costs and potential savings of covering GLP-1 medications (used for weight management) for eligible residents. It directs the Agency to assess actual program savings, consider new federal drug pricing models, discuss outcomes with providers, and report findings to the legislature before the 2027 session. The resolution specifically targets the Agency’s analysis of coverage for an estimated 110,000 Alabama Medicaid members who may qualify under current FDA guidelines. It does not change coverage rules but requires a formal cost-benefit review to inform future decisions.